Weekly fractionated high dose palliative radiotherapy in advanced breast cancer

An institutional phase I/II study to evaluate safety and efficacy of high dose weekly hypofractionated palliative breast radiotherapy in fungating advanced unresectable or metastatic breast cancer

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/09/036217

Enrollment

Registered

2021-09-03

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: palliative radiotherapy: weekly fractionated high dose radiotherapy of 8Gy Control Intervention1: not applicable: not applicable

Eligibility

Inclusion criteria

Inclusion criteria: 1)Histopathologically proven primary breast cancer deemed surgically inoperable 2)Clinically or radiologically T4 disease staged based on 8th Ed TNM staging system, 3)Age >18years, 4)Eastern co-operative oncology group performance score of <=3.

Exclusion criteria

Exclusion criteria: 1) male breast cancer 2) history of second malignancy 3) prior breast or thoracic irradiation

Design outcomes

Primary

Measure	Time frame
Acute radiation toxicityTimepoint: every week during radiotherapy, and 1 month after radiotherapy	—

Secondary

Measure	Time frame
Local control rate, Local progression free survival, Overall survivalTimepoint: every 3 monthly upto 2 years	—

Countries

India

Contacts

Public ContactHaresh K P

AIIMS

drkpharesh@gmail.com8368849729

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026